From DNA Cleavage to Epigenetic Control: CRISPR-Driven Paradigm Shifts in Gene and Cell Therapy
Since its establishment as a programmable genome engineering tool in 2012, the CRISPR-Cas9 system has profoundly reshaped the landscape of life sciences research and is rapidly advancing towards clinical applications. However, the foundational CRISPR-Cas9 approach relies on creating double-strand breaks (DSBs) at target DNA sites—a powerful mechanism that nonetheless carries inherent risks of off-target effects and chromosomal translocations, limiting its safe use in certain sensitive cell types like hematopoietic stem cells.
Now, an authoritative review published in Cell Reports Medicine, titled "Emerging trends in gene and cell therapy: CRISPR in DNA editing and beyond," paints a far more expansive and precise picture of the CRISPR technology landscape. The review highlights a profound paradigm shift within the field: CRISPR is evolving from its initial role as mere "molecular scissors" into a versatile suite of "molecular machines" whose capabilities extend far beyond simple DNA cleavage to encompass base editing, prime editing, and even precise modulation of the epigenome and transcriptome.
Base Editing: Seamless Correction of Single Letters
In direct response to the limitations of traditional CRISPR-Cas9, base editing technologies emerged. By ingeniously fusing a catalytically impaired Cas protein (such as dCas9 or nCas9) with a specific deaminase enzyme, base editors can directly and efficiently convert C•G to T•A or A•T to G•C base pairs without generating DSBs. Since the pioneering work of David Liu's team in 2016, base editors have undergone multiple rounds of optimization, significantly improving their efficiency, specificity, and editing window. For instance, researchers have successfully broadened the targeting scope of cytidine base editors by fusing them with single-stranded DNA-binding protein domains. Moreover, novel adenine transversion editors (AXBEs) now enable precise A•T-to-C•G transversions, dramatically expanding the spectrum of treatable genetic mutations. However, recent studies (e.g., Fiumara et al., 2024) have also issued a cautionary note, revealing that even in the absence of DSBs, base editing can induce unexpected genotoxic effects in human hematopoietic stem cells. This underscores the critical importance of thorough safety assessments before clinical translation.
Prime Editing: A "Search-and-Replace" Approach for Precision Repair
If base editing is a "correction pen," then prime editing is a full-fledged "word processor." Invented by Anzalone et al. in 2019, prime editing technology fuses an nCas9 with a reverse transcriptase and utilizes a specialized prime editing guide RNA (pegRNA). This system can perform all 12 possible base-to-base conversions, as well as small insertions and deletions, with minimal DSB formation. This "search-and-replace" editing mode offers unprecedented potential for correcting up to 90% of known pathogenic point mutations. The technology has seen continuous iterative upgrades: the bi-directional priming Bi-PE system enhances editing efficiency, while twin prime editing strategies enable programmable deletion, replacement, integration, and inversion of large DNA segments. Crucially, researchers are further boosting its efficiency and fidelity in primary cells by manipulating cellular DNA repair determinants, developing more compact and efficient prime editors (e.g., variants evolved via phage-assisted methods), and employing AI-generated small binders (e.g., Park et al.'s 2025 MLH1 binder) to modulate key cellular pathways.
Beyond the Genome: Towards Epigenome and Transcriptome Editing
The potential of CRISPR extends far beyond altering the DNA sequence itself. By fusing dCas9 with various epigenetic modifiers (such as methyltransferases or acetyltransferases) or transcriptional activation/repression domains, scientists can now perform "software-level" reprogramming of the genome. These epigenome and transcriptome editing technologies can persistently turn specific genes on or off without changing the underlying genetic code. This approach opens entirely new avenues for treating disorders caused by gene dosage abnormalities (e.g., haploinsufficiency) or complex polygenic diseases (e.g., neurodegenerative and metabolic syndromes), thereby circumventing the long-term safety concerns associated with permanent DNA alterations.
Challenges and the Path Forward: Towards Safe and Effective Clinical Translation
Despite the increasingly sophisticated CRISPR toolbox, the path to widespread application remains fraught with challenges. Off-target effects, delivery efficiency, immunogenicity, and the variable response of different cell types to editing are significant hurdles to overcome. It is particularly crucial for lifelong cures of genetic diseases to ensure that editing events occur in the correct cells (e.g., long-term repopulating hematopoietic stem cells) and that their stemness is preserved. Furthermore, emerging technologies like TOPO-seq have revealed that DNA topology can influence the off-target activity of both Cas9 and base editors, providing a new dimension for designing safer future editors.
In conclusion, CRISPR technology is transforming from a singular gene knockout tool into an integrated platform for precise DNA editing, epigenetic regulation, and transcriptional intervention. With ongoing refinements to the safety, efficiency, and delivery of these tools, we stand on the brink of a new era of gene and cell therapy—one that is more personalized, precise, and effective than ever before.
